Search

Human cord blood hematopoietic progenitor cell

After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.

Guanethidine

It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.

Riluzole

Riluzole is marketed as Rilutek by Sanofi. … A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.

Fecal microbiota

Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients … [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.

Nicaraven

Equine Botulinum Neurotoxin E Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients. … Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E.

Equine Botulinum Neurotoxin C Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients. … Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C.

Bezafibrate

It decreases low density lipoproteins and increases high density lipoproteins.

Plasminogen

[L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with

Pinaverium

Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.